The narrowing loss reflects winding down of clinical programs rather than revenue generation, but the cash position has strengthened significantly ahead of a potential OLC approval. Traders should monitor the June 29, 2026 PDUFA decision as the key catalyst; if approved, commercial execution will be the next hurdle.
Price Chart
Executive Summary
Unicycive Therapeutics reported its 2025 financial results, showing a narrower net loss of $26.6M (-$1.67/share) versus $37.8M (-$5.65/share) in 2024, driven by lower R&D costs. The company highlighted progress on its OLC NDA, now under FDA review with a PDUFA date of June 29, 2026, and raised cash to $54.9M as of March 30, 2026, extending runway into 2027.
Key Financial Metrics
Key Facts
- Net loss attributable to common stockholders decreased to $26.6M (-$1.67/share) in 2025 from $37.8M (-$5.65/share) in 2024
- R&D expenses dropped to $9.1M in 2025 from $20.0M in 2024 due to reduced clinical trial activity
- G&A expenses rose to $20.4M in 2025 from $12.1M in 2024 due to commercial launch preparations
- Cash, cash equivalents, and marketable securities totaled $54.9M as of March 30, 2026, up from $29.2M at year-end 2025
- FDA accepted OLC NDA resubmission with PDUFA target action date of June 29, 2026
- Company expects funding runway into 2027
Financial Impact
Reduced cash burn from $32.1M in 2024 to $26.6M in 2025, while cash position nearly doubled to $54.9M by Q1 2026
Risk Factors
- No revenue-generating products; entirely dependent on OLC approval and launch success
- Increased G&A spending suggests rising overhead ahead of commercialization
- FDA approval is not guaranteed despite PDUFA acceptance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264502 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 3 | $4.22 | awaiting T+60 | — | $3.58 (−15.17%) |
Sep 29, 2026 27d ago | 8-K | $4.55 | awaiting T+60 | — | $3.58 (−21.32%) |
Aug 12, 2026 10w ago | 8-K | $5.39 | awaiting T+60 | — | $3.58 (−33.58%) |
Jul 2, 2026 16w ago | 8-K | $5.73 $4.81 | ▼ −16.06% | ▼ −19.06% | $3.58 (−37.52%) |
Jun 22, 2026 18w ago | DEFA14A | $7.87 $4.71 | ▼ −40.15% | ▼ −41.90% | $3.58 (−54.51%) |
Jun 16, 2026 18w ago | EFFECT | $7.17 $5.31 | ▲ +25.94% | ▲ +26.94% | $3.58 (+50.07%) |
Jun 5, 2026 20w ago | S-3 | $6.66 $5.05 | ▲ +24.17% | ▲ +27.23% | $3.58 (+46.25%) |
May 12, 2026 23w ago | 8-K | $8.17 $5.05 | ▼ −38.19% | ▼ −42.57% | $3.58 (−56.18%) |
May 12, 2026 23w ago | Press Release | $8.17 $5.05 | ▲ +38.19% | ▲ +42.57% | $3.58 (+56.18%) |
Apr 6, 2026 29w ago | 8-K | $6.62 $5.28 | ▼ −20.24% | ▼ −33.71% | $3.58 (−45.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers